- Home
- ZTR vs LXEO Comparison
ZTR vs LXEO Comparison
Compare ZTR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ZTR | LXEO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.0M | 348.7M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZTR | LXEO |
|---|---|---|
| Price | $6.55 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $20.30 |
| AVG Volume (30 Days) | 104.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.92 | $2.55 |
| 52 Week High | $7.11 | $10.99 |
Technical Indicators
Market Signals| Indicator | ZTR | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 49.55 |
| Support Level | $6.53 | $2.98 |
| Resistance Level | $6.89 | $3.68 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 58.27 | 60.76 |
Price Performance
Historical ComparisonAbout ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.